A clinical stage biotechnology company, ValiRX, said on Wednesday that its VAL201 personalised Phase l/II prostate cancer study brought positive results.
The company wants to build on the initial promising results, and has broadened the study to more clinical sites with more patients.
ValiRx want to use VAL201 to target a specific pathway from the androgen receptor, treating the cancer without suppressing sexual and other functions.
Dr Satu Vainikka, CEO of ValiRx, said: “VAL201 has demonstrated disease stabilisation, with a lower dose than was predicted by our preclinical evaluations. We anticipate that by increasing the dosage we will show a high level of efficacy without compromising the safety and tolerability shown to date to meet the needs of those patients currently under-served by current therapies. ValiRx is entering a very exciting phase, which should result in the crystallisation of substantial value”.